Content area

Abstract

Via Nova Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Via Nova Therapeutics Inc (Via Nova) is a biotechnology company that develops therapies for the treatment of viral diseases. The company's lead product candidate, VNT-101, is a small molecule to treat influenza A infection. Its lead products have demonstrated activity in vitro against seasonal influenza A and highly pathogenic avian influenza (HPAI) H5N1 and H7N9 strains.

Via Nova Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

Details

1007133
Title
Via Nova Therapeutics Inc
Publication title
Number of pages
17
Publication year
2025
Publication date
2025
Publisher
GlobalData plc
Place of publication
London
Country of publication
United Kingdom
Publication subject
Source type
Report
Language of publication
English
Document type
Company Report
Document feature
Mergers & acquisitions
ProQuest document ID
3158368146
Document URL
https://www.proquest.com/reports/via-nova-therapeutics-inc/docview/3158368146/se-2?accountid=208611
Copyright
Copyright GlobalData plc 2025
Last updated
2025-12-29
Database
ProQuest One Academic